Cargando…

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results

AIMS: Discontinuation or non‐publication of trials may hinder scientific progress and violates the commitment made to research participants. We sought to identify the prevalence of discontinuation and non‐publication of heart failure (HF) clinical trials. METHODS AND RESULTS: We conducted a cross‐se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad Shahzeb, Shahid, Izza, Asad, Nava, Greene, Stephen J., Khan, Safi U., Doukky, Rami, Metra, Marco, Anker, Stefan D., Filippatos, Gerasimos S., Fonarow, Gregg C., Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835587/ https://www.ncbi.nlm.nih.gov/pubmed/33191637 http://dx.doi.org/10.1002/ehf2.13099

Ejemplares similares

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Cardiovascular implications of COVID-19 versus influenza infection: a review
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
por: Shahid, Izza, et al.
Publicado: (2022)

Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials
por: Hamid, Arsalan, et al.
Publicado: (2022)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

The Kardashian Index of Cardiologists: Celebrities or Experts?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

The need for increased pragmatism in cardiovascular clinical trials
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Percutaneous Mitral Valve Repair versus Optimal Medical Therapy in Patients with Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis
por: Lodhi, Muhammad Uzair, et al.
Publicado: (2019)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Recognizing the Significance of Outpatient Worsening Heart Failure
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Restoring invisible and abandoned trials: a call for people to publish the findings
Publicado: (2013)

Restoring invisible and abandoned trials: a call for people to publish the findings
por: Doshi, Peter, et al.
Publicado: (2013)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
por: Pocock, Stuart J, et al.
Publicado: (2021)

Frailty and heart failure: State‐of‐the‐art review
por: Talha, Khawaja M., et al.
Publicado: (2023)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design
por: Bartunek, Jozef, et al.
Publicado: (2015)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mg0ctqmm6h4o46oaliq8h8vm19